Fair value measurements and investments (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The fair value of the Company’s financial assets and liabilities measured on a recurring basis were as follows:

	September 30, 2019											December 31, 2018
(U.S. Dollars, in thousands)	Level 1		Level 2			Level 3			Total			Total
Assets
Treasury securities	$	447	$	—		$	—		$	447		$	490
Bone Biologics equity warrants		—		—			—			—			—
Bone Biologics equity securities		—		219			—			219			219
eNeura debt security		—		—			—			—			17,820
eNeura warrant		—		—			—			—			—
Total	$	447	$	219		$	—		$	666		$	18,529
Liabilities
Contingent consideration	$	—	$	—		$	(41,700	)	$	(41,700	)	$	(28,560	)
Deferred compensation plan		—		(1,242	)		—			(1,242	)		(1,275	)
Total	$	—	$	(1,242	)	$	(41,700	)	$	(42,942	)	$	(29,835	)

Schedule of Changes in Valuation of Securities

	Three Months Ended September 30,					Nine Months Ended September 30,
(U.S. Dollars, in thousands)	2019		2018			2019		2018
Bone Biologics equity securities and warrants beginning balance	$	219	$	4,668		$	219	$	2,768
Impact of adoption of ASU 2016-01 recognized in other income (expense), net		—		—			—		1,629
Purchase of additional common stock		—		—			—		500
Fair value adjustments, expirations, and impairments recognized in other income (expense), net		—		(4,449	)		—		(4,678	)
Bone Biologics equity securities and warrants ending balance	$	219	$	219		$	219	$	219

Schedule of Reconciliation For Contingent Consideration Measured At Fair Value Using Significant Unobservable Inputs

The following table provides a reconciliation of the beginning and ending balances for the contingent consideration measured at fair value using significant unobservable inputs (Level 3):

(U.S. Dollars, in thousands)	2019			2018
Contingent consideration at January 1	$	28,560		$	—
Acquisition date fair value		—			25,491
Increase in fair value recognized in acquisition-related amortization and remeasurement		28,140			2,689
Payment made		(15,000	)		—
Contingent consideration at September 30	$	41,700		$	28,180

Fair Value, Inputs, Level 3 [Member]

Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]

Schedule of Reconciliation of Debt Security and Warrant

The following table provides a reconciliation of the beginning and ending balances for the eNeura debt security and Warrant measured and reflected in the condensed consolidated balance sheets at fair value using significant unobservable inputs (Level 3) prior to the settlement discussed above:

(U.S. Dollars, in thousands)	2019			2018
eNeura debt security and Warrant at January 1	$	17,820		$	16,050
Gains or losses recorded for the period
Recognized in other comprehensive income (loss)		(2,593	)		3,200
Change in classification of debt security to held to maturity		(15,227	)		—
Issuance of Warrant as consideration for extension		491			—
Impairment of Warrant		(491	)		—
eNeura debt security and Warrant at September 30	$	—		$	19,250